SKYE News and Press, Skye Bioscience Inc Com From 11/28/23

SBI-100 Ophthalmic Emulsion, a CB1 agonist/activator delivered as a topical eye drop, was developed to treat patients with elevated intraocular pressure Phase 2 study evaluating efficacy and safety using two concentrations of SBI-100 OE vs. placebo, dosing twice a day for 14 days Analysis...

San Diego, California--(Newsfile Corp. - November 21, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing drugs targeting the endocannabinoid system to address diseases including glaucoma and metabolic conditions, will present an overview of its glaucoma prog...

INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...

Skye Bioscience Inc. (SKYE) is expected to report for Q1 2024

2023-10-25 08:50:34 ET More on Skye Bioscience Financial information for Skye Bioscience For further details see: Skye Bioscience posts early-stage data for glaucoma therapy

• SBI-100 OE is well tolerated, with low rate of hyperaemia (8.4%) • Reduced intraocular pressure (23% mean reduction) in healthy volunteers with higher baseline IOP (>17 mm Hg) San Diego, California--(Newsfile Corp. - October 25, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE)...

Phase 1 clinical data to be released in conjunction with Investor Day This document replaces and updates the previous version with the current OTCQB ticker for Skye Bioscience, Inc. San Diego, California--(Newsfile Corp. - October 20, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the...

Phase 1 clinical data to be released in conjunction with Investor Day San Diego, California--(Newsfile Corp. - October 19, 2023) - Skye Bioscience, Inc. (OTCQB: SKYED) ("Skye" or the "Company"), a pharmaceutical company developing drugs targeting the endocannabinoid system, initially through mo...

Patient enrollment starting in Q4 2023 for proof-of-concept P2a study of CB1 agonist Phase 1 study complete and data will be reported in October San Diego, California--(Newsfile Corp. - September 27, 2023) - Skye Bioscience, Inc. (OTCQB: SKYED) ("Skye" or the "Company"), a pharmaceutical co...

San Diego, California--(Newsfile Corp. - September 22, 2023) - Skye Bioscience, Inc. (OTCQB: SKYED) ("Skye" or the "Company"), a pharmaceutical company developing proprietary medicines that modulate the endocannabinoid system to treat diseases with inflammatory, fibrotic, and metabolic processes,...